Área Sanitaria de Santiago de Compostela e Barbanza
Área sanitaria
![Foto de Área Sanitaria de Santiago de Compostela e Barbanza](/img/noimage.png)
![Foto de Mutua de Terrassa](/img/noimage_org.png)
Mutua de Terrassa
Terrassa, EspañaPublicacións en colaboración con investigadores/as de Mutua de Terrassa (128)
2024
-
A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting
Diabetes care, Vol. 47, Núm. 2, pp. 216-224
-
A Prospective, Multicenter, Real-World Registry of Coronary Lithotripsy in Calcified Coronary Arteries: The REPLICA-EPIC18 Study
JACC: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 756-767
-
An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response
Journal of Alzheimer's Disease, Vol. 98, Núm. 2, pp. 601-618
-
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial
The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385
-
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease
Gastroenterologia y Hepatologia
-
Predicting the Length of Mechanical Ventilation in Acute Respiratory Disease Syndrome Using Machine Learning: The PIONEER Study
Journal of Clinical Medicine, Vol. 13, Núm. 6
-
Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn's Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED)
Gastroenterologia y Hepatologia
-
Response to Comment on Beato-Víbora et al. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting. Diabetes Care 2024;47:216-224
Diabetes care, Vol. 47, Núm. 5, pp. e46-e47
-
Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study
Journal of Clinical Medicine, Vol. 13, Núm. 2
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study
European Archives of Psychiatry and Clinical Neuroscience
-
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
Hepatology, Vol. 77, Núm. 4, pp. 1095-1105
-
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901
-
Clinical utility of a personalized and long-term monitoring device for Parkinson's disease in a real clinical practice setting: An expert opinion survey on STAT-ON™
Neurologia, Vol. 38, Núm. 5, pp. 326-333
-
Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort
International Journal of Infectious Diseases, Vol. 137, pp. 134-143
-
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))
Nature communications
-
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
Haematologica, Vol. 108, Núm. 4, pp. 969-980